K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

PURPOSE: CML can be responsive to T cell mediated immunity. K562/GM-CSF is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML associated antigens. A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesyla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Smith, B. Douglas, Kasamon, Yvette L., Kowalski, Jeanne, Gocke, Christopher, Murphy, Kathleen, Miller, Carole B., Garrett-Mayer, Elizabeth, Tsai, Hua-Ling, Qin, Lu, Chia, Christina, Biedrzycki, Barbara, Harding, Thomas C., Tu, Guang Haun, Jones, Richard, Hege, Kristen, Levitsky, Hyam I.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2804932/
https://ncbi.nlm.nih.gov/pubmed/20048335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2046
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars